Oura had the rarest thing in today’s IPO market: genuine demand. The smart ring maker and some of its backers were looking to raise up to $2.2 billion, and multiple reports said the order book was several times covered relative to the shares being sold. That is not a soft book. That is a company that, by most accounts, could have priced on September 29 and been done. Instead, Oura postponed its Nasdaq offering on September 29, 2026, about a week after it formally launched the deal, pointing to market uncertainty while insisting demand remained strong.
The honest explanation is simpler. Coverage from outlets including Reuters has tied the wave of delays to higher interest rates and rising bond yields. A company like Oura, which is asking investors to pay for subscription economics and health-data optionality rather than just hardware revenue, is acutely sensitive to the discount rate. When bond yields move, the math on growth valuations moves with them. CEO Tom Hale said the company has “the luxury of choosing our moment,” and he is right to use it.
A Market That Was Already Running Below Expectations
Oura did not pull its deal in isolation. In recent days, several companies have postponed offerings, with reports naming names such as Holtec and Bamboo Insurance among those stepping back and citing market conditions.
Through mid-September, 109 IPOs had priced in the U.S. in 2026, raising $146.5 billion, according to Renaissance Capital. While the number of IPOs is down about 30% from the comparable period in 2025, proceeds have surged by nearly 400%, highlighting a market dominated by unusually large deals. That surge in dollar terms is heavily influenced by one transaction: SpaceX’s IPO ultimately raised about $85.7 billion in gross proceeds. Strip that out and the market is thin.
With Oura gone for now, two of the most anticipated listings still ahead are Nscale and Anthropic. Nscale, a cloud provider specializing in AI infrastructure, has filed to go public on the New York Stock Exchange under the ticker NSCL, reporting a $1.02 billion net loss on $140.6 million in revenue for the six months ended June 30. Anthropic, meanwhile, has been widely discussed as a potential IPO candidate, with timing and valuation still the subject of market speculation. One is burning cash at an accelerating rate, the other is chasing a valuation that depends entirely on the AI spending cycle holding together. Neither is an obvious buy-at-listing candidate.
Why the Second Year Is Usually the Better Entry
Here is the part most investors skip past. The excitement around an oversubscribed deal obscures a well-documented pattern: history suggests IPOs are often underwhelming entry points for investors because of how and when public investors are able to invest. IPOs have often lagged broader benchmarks in their early years in many academic and market studies, even after adjusting for comparable size and style.
Oura itself is in genuinely strong financial shape, based on its public filing. For the nine months ended June 30, 2026, the company reported $1.21 billion in revenue and net income of $60.8 million. Its business has leaned increasingly into recurring revenue, with membership revenue representing about 20% of sales for that period. The subscription service is priced at $5.99 per month (or $69.99 per year in the U.S.), and as of June 30, 2026, Oura reported 5.0 million paid members, with roughly 72% women and about 27% over age 45. That is a real business with real economics.
The investment argument, then, is not that Oura is flawed. It is that the IPO price is set for the seller. When Oura does eventually list, likely once bond yields stabilize and the fall volatility clears, the first six to twelve months on market will often offer a better price than the initial marketed range that did not clear in late September. A sharp rise in U.S. borrowing costs has tightened the IPO window for closely watched listings, and Oura is unlikely to be the last issuer to step back.
The Wealth Takeaway
Patient investors rarely win the first-day pop. They win by waiting for the lock-up expiration noise to settle, for the first two or three earnings reports to arrive, and for the market to reset a company on fundamentals rather than on marketing heat. Oura walking away from a covered deal is not a warning about the company. It is a reminder that the best time to buy most new listings is not the day they start trading.
